பில் மக்நமர News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from பில் மக்நமர. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In பில் மக்நமர Today - Breaking & Trending Today
Car reviews | Independent road tests carmagazine.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from carmagazine.co.uk Daily Mail and Mail on Sunday newspapers.
Genesis G80: the Korean upstart taking on the German carmakers theweek.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theweek.co.uk Daily Mail and Mail on Sunday newspapers.
Emperor Energy Ltd in trading halt ahead of capital raising announcement proactiveinvestors.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com.au Daily Mail and Mail on Sunday newspapers.
Novartis announces iptacopan met Phase II study primary endpoint in rare kidney disease IgA nephropathy (IgAN) streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Novartis Pharma AG: Novartis announces iptacopan met Phase II study primary endpoint in rare kidney disease IgA nephropathy (IgAN) 3-7 C3 glomerulopathy Basel, 2 1 - Novartis today announced Phase II primary endpoint data showing investigational iptacopan (LNP023) - a first-in-class, oral, targeted factor B inhibitor - reduced protein in the urine (proteinuria), an increasingly recognized surrogate marker correlating with progression to kidney failure 2, and showed promise in stabilizing kidney function in patients with IgA nephropathy (IgAN) 1. The data were presented at the 58 th ERA-EDTA Congress held virtually from June 5-8, 2021. In the Phase II study (NCT03373461), patients (n=112) with IgAN were randomized to placebo or different doses of iptacopan ....